The National Research and Innovation Agency (BRIN) is currently\ndeveloping a treatment for lung cancer. This photodynamic therapy (PDT)\nis X-ray-based, utilising a special photosensitiser made from\nhydroxyapatite nanoparticles combined with zirconium (HApZr).<\/p>\n
Muhammad Basit Febrian, a junior expert researcher at the Research\nCentre for Radioisotope, Radiopharmaceuticals, and Biodosimetry\n(PRTRRB), explained that the research is based on previous findings\nwhere zirconium-doped hydroxyapatite nanoparticles (HApZr) demonstrated\ncytotoxic effects on lung cancer cells. This holds potential as a\ncandidate for lung cancer treatment.<\/p>\n
\u201cThe use of these nanoparticles serves as a drug delivery system and\nas a photosensitising agent capable of accumulating rapidly within cells\nand distributing to target organs,\u201d said Basit, as quoted from the\nofficial BRIN website.<\/p>\n
In this study, the formation of reactive oxygen species (ROS) using\nHApZr nanoparticles was evaluated. Meanwhile, hydrogen peroxide, used as\na positive control, showed an intensity comparable to cells irradiated\nwithout HApZr.<\/p>\n
\u201cWe conducted cytotoxicity tests and cell staining to evaluate the\nmigration of nanoparticles into cancer cells,\u201d Basit explained.<\/p>\n
Animal testing has also been conducted, with results showing that the\naccumulation of free Sc radionuclides in lungs with tumours was\nrelatively low. Test animals treated with HApZr receiving a radiation\ndose of 25 Gy were able to survive, whereas those that did not receive\nthe treatment survived for only two days.<\/p>\n
Furthermore, the maximum recommended dose for HApZr nanoparticles is\n0.5 mg\/kg of body weight. This is based on acute toxicity evaluations,\nwhich showed no side effects or mortality in the test animals.<\/p>\n
This research was carried out by BRIN through the Research Centre for\nRadioisotope, Radiopharmaceuticals, and Biodosimetry (PRTRRB) and the\nResearch Centre for Radiation Process Technology, in collaboration with\nPadjadjaran University and Maranatha Christian University.<\/p>\n
\u201cWe hope this research will not only contribute to the development of\nscience and technology in the fields of radiopharmaceuticals and cancer\ntherapy but also provide benefits for more effective lung cancer therapy\nwith minimal side effects, thereby improving the quality of life and\nlife expectancy of lung cancer patients,\u201d he concluded.<\/p>", "url": "https:\/\/jawawa.id\/newsitem\/indonesia-develops-new-lung-cancer-therapy-1788620026", "image": "" }, "sponsor": "Okusi Associates", "sponsor_url": "https:\/\/okusiassociates.com" }